EPL Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n1eado8vf0qi0mlos3hve84v.pdf

Key Takeaways


B&C Milestone & Growth Drivers

Bakshi: "In the month of September, B&C revenues exceeded that of Oral Care, becoming our largest category. This is a significant milestone and clear demonstration that our strategy is delivering in full and investments being made in this segment are translating into growth and market share gains."

Margin Structure & Cost Recovery

Goyal: "Our gross margin is very strong right now. If you look at our gross margin, the gross contribution in this quarter as reported is 56.7, but that looks depressed purely from optical reasons, because mathematically, as the cost goes up and we recover that through price in the math of it, both the numerator, denominator go up and the percentage looks depressed."

Pricing & Competitive Positioning

Bakshi: "We've learned our lessons, built a pricing muscle. Our sales teams are being very active in the market, and we are proactively leading the price discussion with our customers."

Indovida Merger: Progress & Unanswered Questions


Regional & Category Performance

Market / CategoryTrendCommentary
EAP▲ 40% growthStrongest regional performer.
Europe▲ 30.4% growthTop-line strong but operational challenges in Poland are a margin drag for 2–3 more quarters.
AMESA▲ 28% growthBroad-based strength.
Americas▲ 25% growthU.S. is a significant B&C market where the company is investing to build a larger presence.
India (standalone)▲ 30% growthDriven by market growth and share gains from existing customers; premiumization is driving consumption.
B&C▲ 42.9% growthNow the largest category; growth from share gains, white-space entry, and market growth.
Oral Care▲ 19.2% growthSolid growth despite B&C overtaking it in absolute revenue.
Brazil▲ StrongBuilt over several years by bringing superior quality to the market; cited as a model for new market entry.
Thailand▲ ProgressingLast greenfield plant; entered via Indorama relationship; strong customer pipeline; model to be replicated post-merger.

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthHigh-teens, expected at the higher end closer to 20%Next few quarters
Underlying EBITDA margin20% plusSustained
Europe margin recoveryOperations fully stabilized, margins back to desired levels2–3 quarters
Full-year capex₹625 crore to ₹700 crore, all growth-orientedFY27
Merger completionNCLT approval and closingQ4 FY27 (Q4 consolidation possible but not certain)
Merger synergiesUSD 35–50 million, realized over 3 years post-merger3 years post-merger

Key Metrics

MetricQ2 FY27
Revenue growth30% YoY, highest ever growth declared by the company
Underlying revenue growth20.3% YoY, excluding pass-through impact of higher raw material prices
EBITDA growth17.6% YoY, 16th consecutive quarter of double-digit EBITDA growth
Reported EBITDA margin18.9%
Underlying EBITDA margin20.4%, excluding inflation-led pricing in denominator
PAT growth5.6% YoY, impacted by higher depreciation, higher effective tax rate due to country mix, and adverse forex movements
Gross margin (reported)56.7%
Gross margin (underlying)60.5%, excluding inflationary cost
H1 FY27 capex₹315 crore, almost 90% increase over same period last year
Full-year capex guidance₹625 crore to ₹700 crore
Beauty & Cosmetics revenue growth42.9% YoY; became largest category in September, overtaking Oral Care
Oral Care revenue growth19.2% YoY
Europe revenue growth30.4% YoY
EAP region revenue growth40% YoY
AMESA region revenue growth28% YoY
Americas region revenue growth25% YoY
India stand-alone revenue growth30% YoY
Global market share gain130 basis points in last 1 year, per management estimate
Sustainable tubes share41% of product mix
Normal capacity utilization60% to 65% on rated capacity
Indovida merger synergy target$35 million to $50 million over 3 years post-merger
Post-merger expected debt-to-EBITDA ratio0.2x to 0.25x
Post-merger share count51 crore shares
Combined PAT (EPL + Indovida)~₹800 crore+ (per an analyst's math)
FY27 revenue estimate~₹5,900 crore (±1–2%), implied by high-teens/20% growth guidance for H2 (per an analyst's math)